Drug intelligence / Profile preview

ISM4808

Development stage: Phase 1
Lead developer: InSilico Medicine
Modality: Small Molecules
Administration: Oral

Overview

ISM4808 is a novel drug candidate developed by Insilico Medicine using its artificial intelligence (AI) platform. It functions as a prolyl hydroxylase domain (PHD) inhibitor. The drug is being developed for the treatment of anemia associated with chronic kidney disease (CKD). Insilico Medicine has licensed ISM4808 to TaiGen Biotechnology, leveraging TaiGen's clinical and market expertise in Asia to advance this preclinical asset.

Targets

EGLN1 (Prolyl hydroxylase domain-containing protein 2)PHD1 (Prolyl hydroxylase domain-containing protein 1)

Beyond the preview

Go deeper on ISM4808.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISM4808.

Explore the full profile